Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
MicroRNAs01:22

MicroRNAs

24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
MicroRNAs01:22

MicroRNAs

4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2018
Same author

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018
Same author

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Therapeutic advances in medical oncology·2018
Same author

Stress effects on FosB and interleukin-8 (<i>IL8</i>)-driven ovarian cancer growth and metastasis.

The Journal of biological chemistry·2018
Same author

Stress, inflammation, and eicosanoids: an emerging perspective.

Cancer metastasis reviews·2018
Same author

Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.

Cancer·2018

Related Experiment Video

Updated: Feb 26, 2026

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
08:36

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

15.1K

Chitosan Nanoparticles for miRNA Delivery.

Merve Denizli1, Burcu Aslan1,2, Lingegowda S Mangala2,3

  • 1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Methods in Molecular Biology (Clifton, N.J.)
|July 22, 2017
PubMed
Summary
This summary is machine-generated.

Chitosan nanoparticles effectively deliver microRNAs for cancer therapy, enhancing stability and cellular uptake. This approach shows significant antitumor activity after intravenous administration.

Keywords:
Chitosan nanoparticlesProstate cancerRNA interferencemiR-34amicroRNA delivery

More Related Videos

Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
05:36

Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles

Published on: October 4, 2024

2.7K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
08:36

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

15.1K
Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
05:36

Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles

Published on: October 4, 2024

2.7K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.6K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • RNA interference (RNAi) offers therapeutic potential, with microRNA (miRNA)-based strategies attractive for their multi-target capabilities.
  • In vivo delivery of nucleic acids, including miRNAs, faces challenges in stability, cellular uptake, and targeted delivery.
  • Chitosan nanoparticles present a viable platform for nucleotide delivery, addressing these limitations.

Purpose of the Study:

  • To develop and characterize chitosan nanoparticles for effective in vivo microRNA delivery.
  • To evaluate the potential of this nanoplatform for therapeutic applications, specifically targeting cancer.

Main Methods:

  • Development and characterization of chitosan nanoparticles for nucleotide delivery.
  • Assessment of nanoparticle stability and cellular uptake efficiency.
  • Evaluation of target modulation and antitumor activity following intravenous administration in preclinical models.

Main Results:

  • Chitosan nanoparticles demonstrated robust delivery of microRNAs, improving stability and cellular uptake.
  • The nanoplatform facilitated significant target modulation.
  • Intravenous administration of the chitosan nanoparticle-miRNA complex exhibited notable antitumor activity.

Conclusions:

  • Chitosan nanoparticles are a promising platform for overcoming in vivo delivery challenges associated with microRNAs.
  • This nanodelivery system holds potential for effective cancer therapy through robust target modulation and antitumor effects.